Markerstudy in £200m investment deal led by Pollen Street Capital

Money

QIC is also set to participate in the transaction, as Markerstudy says it plans to grow organically and through acquisitions.

Markerstudy Group has revealed an agreement for a £200m investment led by Pollen Street Capital.

The transaction will see Pollen Street partner with and make an investment alongside the existing founder team.

Qatar Insurance Company (QIC), which bought Markerstudy’s insurance companies for £107.8m via its subsidiary Qatar Re in July 2018, will also participate in the transaction.

Expansion
Markerstudy stated that it will use the investment to deliver an “ambitious and sustainable” growth

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@insuranceage.co.uk.

You are currently unable to copy this content. Please contact info@insuranceage.co.uk to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Insurance Age? View our subscription options

Register

Sign up and gain access to five complimentary news articles every month.

Already have an account? Sign in here

This address will be used to create your account

Polaris at 30 – Ray Vincent

As insurance industry owned Polaris celebrates its 30th birthday, Insurance Age asks experts for their recollections on the dawn of digital trading and what is coming next.

Meet the MGA: Kayzen Specialty

Kayzen Specialty founder and CEO Charles Boorman explains to Jonathan Swift his plans for the MGA to be a go-to market for financial lines through continuous improvement across its three pillars of broker-centric, underwriter-fronted and tech-focused.

Most read articles loading...

You need to sign in to use this feature. If you don’t have an Insurance Age account, please register now.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an indvidual account here: